Participants in a randomized comparison of investigational psilocybin and escitalopram entered the trial with higher expectations for psilocybin. Yet higher expectations for psilocybin did not predict therapeutic response in that arm. Higher expectations for escitalopram were associated with better outcomes among participants assigned to escitalopram.
Expectancy and suggestibility measured different things
The analysis used data from 55 participants with major depressive disorder. The researchers used mixed linear models to examine how pretreatment efficacy expectations and baseline traits related to outcomes in each treatment arm. Trait suggestibility was associated with therapeutic response in the psilocybin arm. The analysis did not find that association in the escitalopram arm.
What randomization can tell us
The trial randomized treatment assignment. Participants’ expectations and suggestibility were measured characteristics. Their associations with outcomes are observational, even within a randomized trial. The sample size also limits how much weight to give an association that appears in one arm or a result that fails to reach statistical significance in the other.
Pretreatment expectancy answers a specific question about beliefs before exposure. Whether participants inferred their assignment after experiencing treatment effects is a separate question about masking. A report assessing bias should specify which of those questions the available evidence addresses.
Source Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression, Psychological Medicine.